Lipid-Nanoparticle Based Genomic Medicines Market Size is valued at USD 2.6 Bn in 2024 and is predicted to reach USD 22.0 Bn by the year 2031 at a 31.0 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The shift towards customized medicine is driving the lipid-nanoparticle-based genomic medicines market.
- The rise in mRNA-based therapeutics, enabled by lipid nanoparticles, is a significant growth factor.
- North America dominated the market and accounted for a global revenue share in 2023.
- Navigating the complex regulatory landscape and achieving approvals for LNP-based genomic medicines is another key challenge for the market.
LNP-based genetic medicines are leading the way in personalized and precision medicine, providing hopeful new therapy possibilities for a diverse array of disorders. Their development and therapeutic application are subjects of ongoing research, having the potential to completely transform the approach to treating genetic and infectious disorders.
Ongoing breakthroughs in nanotechnology, including lipid-based nanoparticles, are driving the development of precise and efficient delivery techniques for genetic therapies, enhancing the effectiveness of these medications. Another driving force behind the adoption of genomic pharmaceuticals, specifically mRNA-based treatments, is their potential to treat a variety of ailments, including genetic disorders, cancer, and infectious diseases. This necessitates the development of delivery mechanisms for lipid nanoparticles. The use of cancer apps serves as an additional incentive.
In this changing landscape, research, strategic alliances, and regulatory advances emphasize lipid-nanoparticle-based genetic medicines as transformative treatments in the age of personalised healthcare. Recent technology platforms include lipid nanoparticles (LNPs). With LNP delivery technologies, over two billion people have received COVID-19 mRNA immunizations or boosters.
Competitive Landscape
Some Major Key Players In The Lipid-Nanoparticle Based Genomic Medicines Market:
- Moderna Inc.
- Pfizer Inc.
- BioNTech SE
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- CureVac N.V.
- Lipocalyx
- Acuitas Therapeutics
- Precision NanoSystems Inc.
- IONTAS Limited
- Genevant Sciences
- Roche Holding AG
- Alnylam Pharmaceuticals Inc.
- SiO2 Materials Science
- Ethris GmbH
- BIOVECTRA
- Avanti Polar Lipids, Inc. (Croda International Plc.),
- Recipharm AB
- eTheRNA
- ST Pharm Co Ltd,
- Other Prominent Players
Market Segmentation:
The Lipid-Nanoparticle Genomic Medicines Market can be segmented based on MoA, Application, and End-User. By MoA, the market is segmented into Gene Addition/Replacement, Gene Expression Control, Gene Editing, DNA/RNA Vaccines. The Application segment of the market includes Cancer Treatment, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, and Others. By Therapeutic Payload, the market is segmented into mRNA-based Therapeutics, siRNA-based Therapeutics, miRNA-based Therapeutics, and Other Genomic Medicines. The End-User segment comprises Hospitals, Biopharmaceutical Companies, Research Institutes, and Others.
North America Has A Significant Revenue Share In The Lipid-Nanoparticle Genomic Medicines Market Region.
In the region, North America leads the Lipid-Nanoparticle Genomic Medicines Market in terms of revenue share. The broad use of mRNA-based vaccinations and treatments is the main trend in North America. Sufficient funding for biopharmaceutical research fosters innovation, with a particular emphasis on extending the use of lipid-nanoparticle genetic therapies to disorders such as neurodegenerative ones.
The region's leadership in the development of genetic medicine is partly attributed to regulatory backing and partnerships between academics and business. Europe and the Asia-Pacific region place a strong emphasis on sustainable lipid nanoparticle technology. Research on environmentally friendly lipid formulations and resolving environmental issues are trends. Additionally, the region is home to cooperative efforts in precision oncology, with an emphasis on lipid-based drug delivery system improvements and personalised genetic therapy.
Recent Developments:
- In December 2023, ReciBioPharm, the advanced therapies division of Recipharm, and biotech company Acuitas Therapeutics are elevating their partnership to offer technology transfers and CGMP manufacturing for customers licensing Acuitas’ lipid nanoparticle (LNP) formulations for mRNA-based therapeutics and vaccines.
Lipid-Nanoparticle Based Genomic Medicines Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 2.6 Bn |
|
Revenue Forecast In 2031 |
USD 22.0 Bn |
|
Growth Rate CAGR |
CAGR of 31.0% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By MoA, Application and End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Moderna Inc., Pfizer Inc., BioNTech SE, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., CureVac N.V., Lipocalyx, Acuitas Therapeutics, Precision NanoSystems Inc., IONTAS Limited, Genevant Sciences, Roche Holding AG, Alnylam Pharmaceuticals Inc., SiO2 Materials Science, Ethris GmbH, BIOVECTRA, Avanti Polar Lipids, Inc. (Croda International Plc.), Recipharm AB, eTheRNA, ST Pharm Co Ltd, and Other market players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
